DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Continued Development of an Implantable Sustained Release System for the Prevention of Malaria.
Annual rept. 24 Jun 74-24 Mar 75,
DYNATECH R/D CO CAMBRIDGE MASS
Pagination or Media Count:
Uniform, sustained release of WR-7557 has been achieved in vitro. The effects of polymer type, molecular weight, drug content, and implant shape on the rate of WR-7557 in vitro release have been evaluated. Two 3-month WR-7557 systems have emerged 116-in. diameter beads of a 50 L-lactic50 dl-lactic acid copolymer containing 33 WR-7557, and a 144-177 micrometer powder of a 100 poly-L-lactic acid containing 20 WR-7557. In vivo evaluation in mice of 116-in. diameter beads of a 90 L-lactic10 glycolic acid copolymer containing 10 WR-7557 has demonstrated drug release too slow for a 3-month system. Steady release of WR-158122 from a less than 44 micrometer spray dried powder of a 90 L-lactic10 glycolic acid copolymer containing 60 WR-158122 has also been achieved in vitro and in vivo, but at a rate much too slow for a 3-month system. In vitro experiments with glycolic, lactic, and citric acid salts of WR-158122 have shown substantial increases in the release rate of this drug. Author
APPROVED FOR PUBLIC RELEASE